Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance

MLA

Robert Flisiak, et al. “Real-World Experience with Molnupiravir during the Period of SARS-CoV-2 Omicron Variant Dominance.” Pharmacological Reports, vol. 74, Aug. 2022, pp. 1279–85. EBSCOhost, https://doi.org/10.1007/s43440-022-00408-6.

APA

Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, Krystyna Dobrowolska, Jerzy Jaroszewicz, Anna Moniuszko-Malinowska, Marta Rorat, Regina Podlasin, Olga Tronina, & Piotr Rzymski. (2022). Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance. Pharmacological Reports, 74, 1279–1285. https://doi.org/10.1007/s43440-022-00408-6

Chicago

Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, Krystyna Dobrowolska, et al. 2022. “Real-World Experience with Molnupiravir during the Period of SARS-CoV-2 Omicron Variant Dominance.” Pharmacological Reports 74 (August): 1279–85. doi:10.1007/s43440-022-00408-6.